Cingulate Inc. — Form 8-K Summary
Reporting context: The 8-K reports an employment-agreement amendment dated September 30, 2026; the report was signed October 2, 2026. Cingulate Therapeutics LLC, a wholly owned subsidiary, entered into the amendment with Matthew N. Brams, Executive Vice President and Chief Medical Officer.
Material change
The amendment extends the trial period for Mr. Brams’ full-time employment from September 30, 2026, to December 31, 2026. It is effective September 30, 2026.
Financial information and outlook
This 8-K does not report revenue, profit, cash flow, margins, debt, liquidity, financial guidance, or other financial metrics. It provides no additional business outlook or discussion of risks or contingencies.
Key facts to verify
- Review Exhibit 10.1, the full text of Amendment No. 2, for any terms beyond the trial-period extension.
- Confirm the outcome of the trial period and Mr. Brams’ employment status after December 31, 2026, in subsequent company disclosures.